期刊文献+

中医药联合PD-1单抗治疗难治性弥漫大B细胞淋巴瘤1例 被引量:1

Successful Reversal of a Refractory Diffuse Large B-cell Lymphoma by Chinese Medicine Combined with PD-1 Monoclonal Antibody
原文传递
导出
摘要 给予1例经多线治疗失败的弥漫大B细胞淋巴瘤患者中药联合特瑞普利单抗注射液治疗:特瑞普利单抗注射液240mg/次静脉输注,结合二陈汤合消瘰丸加减坚持服用。治疗3个月后患者身体状态从PS评分3~4分恢复到0分,经PET-CT检查全身多发肿大淋巴结缩小超过60%,疗效评价PR。第6次应用特瑞普利单抗注射液治疗时,复查甲状腺功能提示:TSH明显高于正常范围,T3、T4略低于正常范围,无特殊临床症状,诊断为继发性甲状腺功能减退,给予左甲状腺素钠片口服治疗后甲状腺功能恢复正常。该病案可为难治性非霍奇金淋巴瘤的临床治疗提供借鉴。 A case of diffuse large B cell lymphoma with multiple-line chemotherapy failure was treated with Chinese medicine combined with Toripalimab Injection:Toripalimab Injection 240 mg/times,intravenous infusion,combined with traditional Chinese medicine Erchendecoction and Xiaolei pill adhere to oral.Three months after treatment,the patient’s physical condition recovered from 3-4 points of PS score to 0 points,and the lymph nodes with multiple enlarged body were reduced by more than 60%after PET-CT examination.The curative effect was evaluated as PR.The reexamination of thyroid function in the sixth treatment with Toripalimab Injection showed that the TSH of thyroid function was significantly higher than the normal range,the T3、T4 was slightly lower than the normal range,there was no special clinical symptoms,and the diagnosis was secondary hypothyroidism.Thyroid function returned to normal after oral treatment with levothyroxine sodium tablets.It can provide a reference for the clinical treatment of refractory non-Hodgkin lymphoma.
作者 顾刚寿 崔淑娟 李成彪 Gu Gangshou;Cui Shujuan;Li Chengbiao(People's Hospital of Wuwei City,Wuwei 733000,China;Liangzhou Hospital of Wuwei City,Wuwei 733000,China)
出处 《亚太传统医药》 2021年第7期84-86,共3页 Asia-Pacific Traditional Medicine
关键词 难治性非霍奇金淋巴瘤 二陈汤 消瘰丸 PD-1抑制剂 特瑞普利单抗 中西医结合 Refractory Non-Hodgkin Lymphoma Erchen Decoction Xiao Luo Piu PD-1Inhibitors Toripalimab Injection Integrated Traditional and Western Medicine
  • 相关文献

参考文献4

二级参考文献34

  • 1Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 2Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 4Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 5Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 6Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 7Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 8Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.
  • 9Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69.
  • 10NCCN Guidelines. Non-Hodgkin' s Lymphomas, version 2.2012.

共引文献334

同被引文献26

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部